Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Widmark A, et al. Among authors: lund ja. Lancet. 2009 Jan 24;373(9660):301-8. doi: 10.1016/S0140-6736(08)61815-2. Epub 2008 Dec 16. Lancet. 2009. PMID: 19091394 Free article. Clinical Trial.
Second Cancers in Patients With Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment With or Without Radical Radiation Therapy: Long-Term Follow-up of the Scandinavian Prostate Cancer Group-7 Trial.
Aksnessæther BY, Myklebust TÅ, Solberg A, Klepp OH, Skovlund E, Hoff SR, Fosså SD, Widmark A, Lund JÅ. Aksnessæther BY, et al. Among authors: lund ja. Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):706-714. doi: 10.1016/j.ijrobp.2019.11.027. Epub 2019 Nov 28. Int J Radiat Oncol Biol Phys. 2020. PMID: 31786279 Clinical Trial.
Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial.
Fransson P, Lund JA, Damber JE, Klepp O, Wiklund F, Fosså S, Widmark A; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Fransson P, et al. Among authors: lund ja. Lancet Oncol. 2009 Apr;10(4):370-80. doi: 10.1016/S1470-2045(09)70027-0. Epub 2009 Mar 13. Lancet Oncol. 2009. PMID: 19286422 Clinical Trial.
Second cancers in radically treated Norwegian prostate cancer patients.
Aksnessæther BY, Lund JÅ, Myklebust TÅ, Klepp OH, Skovlund E, Roth Hoff S, Solberg A. Aksnessæther BY, et al. Among authors: lund ja. Acta Oncol. 2019 Jun;58(6):838-844. doi: 10.1080/0284186X.2019.1581377. Epub 2019 Mar 25. Acta Oncol. 2019. PMID: 30905229
In Reply to Sari et al.
Aksnessæther BY, Myklebust TÅ, Solberg A, Klepp OH, Skovlund E, Hoff SR, Fosså SD, Widmark A, Lund JÅ. Aksnessæther BY, et al. Among authors: lund ja. Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):388-389. doi: 10.1016/j.ijrobp.2020.02.027. Epub 2020 Feb 26. Int J Radiat Oncol Biol Phys. 2020. PMID: 32112877 No abstract available.
Radiotherapy for prostate cancer - Does daily image guidance with tighter margins improve patient reported outcomes compared to weekly orthogonal verified irradiation? Results from a randomized controlled trial.
Tøndel H, Lund JÅ, Lydersen S, Wanderås AD, Aksnessæther B, Jensen CA, Kaasa S, Solberg A. Tøndel H, et al. Among authors: lund ja. Radiother Oncol. 2018 Feb;126(2):229-235. doi: 10.1016/j.radonc.2017.10.029. Epub 2018 Feb 3. Radiother Oncol. 2018. PMID: 29398152 Clinical Trial.
Response to Alongi et al.
Tøndel H, Lund JÅ, Solberg A. Tøndel H, et al. Among authors: lund ja. Radiother Oncol. 2018 Aug;128(2):391. doi: 10.1016/j.radonc.2018.05.008. Epub 2018 Jun 12. Radiother Oncol. 2018. PMID: 29907339 No abstract available.
59 results